CAS9 Technology Market Research Report- Forecast To 2030

CAS9 Technology Market: Product Type (Consumables and Vectors), Application (Genome Engineering, Disease Models and In Vitro Genetic Depletion), Delivery Method (Physical Delivery Methods, Viral Delivery Methods and Non-Viral Delivery Methods) and End User (Biotechnology & Pharmaceutical Companies and Academic & Research Institutes) and Region - Global Forecast Till 2030

ID: MRFR/ICT/1532-CR | February 2019 | Region: Global | 153 Pages         

CAS9 Technology Market

The global CAS9 technology market size is USD 6.72 Billion expected to record a CAGR of 11.30% during the review period (2020–2030).

Segmentation

By Product Type Consumables And Vectors
By Application Genome Engineering Disease Models And In Vitro Genetic Depletion
By Delivery Method Physical Delivery Methods Viral Delivery Methods And Non Viral Delivery Methods
By End User Biotechnology & Pharmaceutical Companies And Academic & Research Institutes

Key Players

  • Cellecta Inc.
  • abm Inc.
  • GenScript
  • CRISPR Therapeutic
  • Intellia Therapeutics Inc.
  • GE Healthcare
  • Takara Bio Inc.
  • AstraZeneca
  • PLC
  • Merck KGaA
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation (Integrated DNA Technologies Inc.)
  • New England Biolabs
  • OriGene Technologies Inc.
  • Lonza Group
  • and Thermo Fisher Scientific

Drivers

  • Growing awareness regarding biotechnology techniques and products and the increasing acceptance of gene therapy-based treatments are the major driving factors for the CAS9 technology market growth.
Speak to Analyst Request a Free Sample

CAS9 Technology Market Snapshot:


A strong commercial interest and rising application opportunities to boost the global CAS9 technology market in the forthcoming years. The market is projected to soar at a compound annual growth rate of 16.48% between 2018 and 2030. Emergence of genome editing or gene editing with engineered nucleases has taken genetic engineering to the next level. CAS9 technology is quickly gaining prominence as a genome editing tool. Advanced countries in North America and Europe are witnessing a faster uptake of the technology. Asia Pacific is also likely to present lucrative growth opportunities to market players during the review period.

This MRFR report offers a detailed analysis of the CAS9 technology market. It also includes five-year revenue analysis, ending in 2030. The report starts with a market introduction where point such as scope of study, research objective and list of assumptions are discussed. This is followed by a through discussion on market dynamics. Next, an in-depth market segment and segment analysis is furnished. This report also includes a market competitive landscape, which covers some of the top companies operating in the CAS9 technology market.


CAS9 Technology Market Companies Covered:
Cellecta, Inc., abm Inc., GenScript, CRISPR Therapeutic, Intellia Therapeutics, Inc., GE Healthcare, Takara Bio, Inc., AstraZeneca, PLC, Merck KGaA, Bio-Rad Laboratories, Inc., Danaher Corporation (Integrated DNA Technologies, Inc.), New England Biolabs, OriGene Technologies, Inc., Lonza Group, and Thermo Fisher Scientific.


The report offers insights into the leading market players and presents an assessment of their current market position. Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M&A activities, and the latest R&D initiatives is also available in the report


Research Methodology:
MRFR employs a range of scrupulously chosen methods to build a research model for drawing mission-critical insights. Use of primary methods such as personal interviews with industry decision makers allows to get an inside look. Then, the findings from primary research methods are avouched by secondary research methods such as annual reports, annual reports, SEC filings, etc. To guarantee transparency and adhere to provide reliable market data, top-down and bottom-up approaches are integrated into the research model. This allows data analysts to offer recognition of many pivotal market figures. These figures are then used to postulate weighty analysis coinciding with timely insights.


Other Description:



  • Market Denomination- USD Mn

  • Base Year- 2017

  • Forecast Period- from 2018 to 2023


For the scope of the research, MRFR’s report offers a comprehensive segmental analysis of the global market for CAS9 technology


Product Type:



  • Consumables

  • Vectors


Application:



  • Genome engineering

  • Disease models

  • In vitro genetic depletion


Delivery Method:



  • Physical delivery methods

  • Viral delivery methods

  • Non-viral delivery methods


End User:



  • Biotechnology & pharmaceutical companies

  • Academic & research institutes


By Region:



  • North America

  • Europe

  • Asia Pacific

  • The Middle East & Africa (MEA)

  • Latin America.


Intended Audience:



  • Pharmaceutical & Biopharmaceutical companies

  • Biotechnology Companies

  • Government Research Laboratories 

  • Independent Research Laboratories

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories



Report Scope:
Report Attribute/Metric Details
  Market Size   2030: USD 6.72 Billion
  CAGR   11.30%
  Base Year   2020
  Forecast Period   2020-2030
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Product Type, Delivery Method, Application
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Cellecta, Inc., abm Inc., GenScript, CRISPR Therapeutic, Intellia Therapeutics, Inc., GE Healthcare, Takara Bio, Inc., AstraZeneca, PLC, Merck KGaA, Bio-Rad Laboratories, Inc., Danaher Corporation (Integrated DNA Technologies, Inc.), New England Biolabs, OriGene Technologies, Inc., Lonza Group, and Thermo Fisher Scientific
  Key Market Opportunities

  • Advanced countries in North America and Europe are witnessing a faster uptake of the technology. \r\n
  • Asia Pacific is also likely to present lucrative growth opportunities to market players during the review period.
  •   Key Market Drivers   Growing awareness regarding biotechnology techniques and products and the increasing acceptance of gene therapy-based treatments are the major driving factors for the CAS9 technology market growth.


    Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The global CAS9 technology market is expected to record a CAGR of 11.30% during the review period (2020–2030).

    Growing awareness regarding biotechnology techniques and products and the increasing acceptance of gene therapy-based treatments are the major driving factors for the CAS9 technology market growth.

    the associated risk factors and high prices are one of the impeding factors for the growth of the CAS9 technology market.

    The North American region is expected to acquire the largest market share at 11.52% CAGR.

    The physical delivery method segment of the CAS9 technology market is expanding at a 29.11% CAGR over the review period.

    A few significant players of the CAS9 technology market are tech giants such as Thermo Fisher Scientific, AstraZeneca, PLC, Merck KGaA, and Bio-Rad Laboratories, Inc, among others.

    The genome engineering segment is expected to record the highest growth over the assessment period.

    Global CAS9 technology market: Competitive Landscape


    A number of industries are using CAS9 technology for the development and production of new drugs for various diseases. Through extensive research, it is found out that the market players have adopted different strategies to develop better and cost-effective products, also under gone mergers and acquisition. Some key players operating in this market: Intellia Therapeutics, Inc, Novartis AG, Bayer AG, and CRISPR THERAPEUTICS.  Many leading players are concentrated in the Americas owing to well-established market and high healthcare expenditures; these players have expanded their market in other region as well.


    Intellia Therapeutics, Inc a gene-editing company and develops novel therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. It is involved in developing treatments with the potential to cure serious diseases such as cancer, autoimmune diseases, liver diseases, and others. The company is also involved in mergers and acquisitions. In April 2016 Intellia Therapeutics, Inc   collaborated with Regeneron Pharmaceuticals, Inc. to advance the CRISPR/Cas gene-editing technology for in vivo therapeutic development.


    CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. Its leading product targets blood diseases β-thalassemia and sickle cell disease using the ex vivo approach. The key strategies adopted by the company are mergers, acquisition and strategic collaborations to increase their business. In August 2017, the company announced its collaboration with Massachusetts General Hospital to Research Use of CRISPR/Cas9 in T Cell Cancer Therapies, thus enabling the development of next generation of T cell therapies in oncology.


    Bayer AG is a German pharmaceutical and life sciences company. It operates in a wide range of areas of business including human and veterinary pharmaceuticals, consumer healthcare products, agricultural chemicals and biotechnology products, and high-value polymers. The pharmaceuticals division of the company focuses on prescription products in the areas of cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology, and ophthalmology. In August 2016, Bayer AG and CRISPR Therapeutics started a joint venture, named Casebia Therapeutics, in Cambridge to develop, discover and commercialize new therapeutics to cure blood blindness, disorders, and congenital heart disease.


    Each of them is committed to providing high-quality products to enhance patient care. These players established themselves as major companies across the globe. They are investing in research, awareness, marketing and technology advancement. The also focus on acquisitions, collaborations, partnerships, expansion and new product launches to obtain maximum market share.